Endonovo Therapeutics Announces LOI to Acquire Specialty Construction Company
June 09, 2022 14:02 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, June 09, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB:ENDV) today announced a Letter of Intent to purchase a highly-regarded market leading specialty concrete services...
Endonovo Therapeutics Signs Agreement with NAMSA to Develop Reimbursement Strategy for Endonovo Medical Products
April 25, 2022 09:08 ET
|
Endonovo Therapeutics, Inc.
LOS ANGELES, CA, April 25, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB:ENDV) today announced an agreement with NAMSA – a leading Global Contract Research Organization (CRO) and...
$5 Million Common Stock Offering for Endonovo Therapeutics Designed to Advance SofPulse® Process for Medical Reimbursement
April 11, 2022 09:08 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, April 11, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced significant advancement in the of process to obtain medical reimbursements for its...
Endonovo Therapeutics Inc. (ENDV) Appoints Garry Michael Kann As Head of Corporate Development To Identify And Acquire Profitable Companies For Endonovo
March 01, 2022 09:10 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, March 01, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTC-ENDV), a developer and distributor of Innovative Medical Devices is pleased to announce that it has appointed...
Endonovo Therapeutics Inc. (ENDV) Announces it has filed a Regulation A+ Financing & Retained Dalmore Group to Provide Operations & Compliance
February 16, 2022 09:10 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTC-ENDV) an Innovative Medical Devices developer and distributor is pleased to announce it has filed a Regulation A+...
Endonovo Therapeutics Issues Shareholder Update
October 12, 2021 16:05 ET
|
Endonovo Therapeutics, Inc.
High-Growth Acquisition Approaches Completion, Expected To Augment Core Business And Drive Long-Term Shareholder Value Los Angeles, CA, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc....
Stanford University Orthopedic Study Collaboration with Endonovo Therapeutics SofPulse® Devices Moves Forward
May 11, 2021 08:00 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, May 11, 2021 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced completion of Shipment of SofPulse® tPEMF Devices for use in...
Endonovo Therapeutics’ Offers FDA Cleared Solution to Opioid Epidemic Which Has Significantly Increased During the COVID Pandemic.
October 08, 2020 08:00 ET
|
Endonovo Therapeutics, Inc.
LOS ANGELES, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today a new marketing and public awareness campaign around their FDA...
Endonovo Therapeutics Announces Encore Live Webinar of Baylor College of Medicine Study For Patients Undergoing Cardiothoracic Surgery Showing Reduction of Pain and Opioid Use With Significant Reduction of Length of Stay Using SofPulse®
September 09, 2020 08:00 ET
|
Endonovo Therapeutics, Inc.
LOS ANGELES, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced an additional opportunity to view a live webinar presentation...
Endonovo Therapeutics, Inc. Announces Second Quarter Fiscal 2020 Financial Results
August 20, 2020 14:51 ET
|
Endonovo Therapeutics, Inc.
LOS ANGELES, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced financial and operating results for the second quarter ended...